Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    LakeShore Biopharma Co. L...

    NASDAQ: LSB · Real-Time Price · USD
    0.96
    -0.03 (-3.02%)
    At close: Jun 13, 2025, 3:50 PM
    0.92
    -4.79%
    After-hours: Jun 13, 2025, 04:00 PM EDT

    LakeShore Biopharma Ltd Statistics

    Share Statistics

    LakeShore Biopharma Ltd has 19.08M shares outstanding. The number of shares has increased by -89.87% in one year.

    Shares Outstanding

    n/a
    		 19.08M

    Shares Change (YoY)

    n/a
    		 -89.87%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 3.3M

    Failed to Deliver (FTD) Shares

    n/a
    		 690

    FTD / Avg. Volume

    n/a
    		 3.2%

    Short Selling Information

    The latest short interest is 3.85K, so 0.02% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.85K

    Short % of Shares Out

    n/a
    		 0.02%

    Short % of Float

    n/a
    		 0.11%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -12.93 and the forward PE ratio is 0.71. LakeShore Biopharma Ltd's PEG ratio is -0.11.

    PE Ratio

    n/a
    		 -12.93

    Forward PE

    n/a
    		 0.71

    PS Ratio

    n/a
    		 9.77

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 9.58

    P/FCF Ratio

    n/a
    		 -16.51

    PEG Ratio

    n/a
    		 -0.11
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for LakeShore Biopharma Ltd.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.73.

    Current Ratio

    n/a
    		 1.13

    Quick Ratio

    n/a
    		 0.87

    Debt / Equity

    n/a
    		 0.73

    Debt / EBITDA

    n/a
    		 -1.15

    Debt / FCF

    n/a
    		 -1.25

    Interest Coverage

    n/a
    		 -10.05

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $756,488.46

    Profits Per Employee

    n/a
    		 $-571,853.39

    Employee Count

    n/a
    		 758

    Asset Turnover

    n/a
    		 0.38

    Inventory Turnover

    n/a
    		 0.58

    Taxes

    Income Tax

    n/a
    		 -21.73M

    Effective Tax Rate

    n/a
    		 4.77%

    Stock Price Statistics

    The stock price has increased by -86.25% in the last 52 weeks. The beta is 0.6, so LakeShore Biopharma Ltd's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.6

    52-Week Price Change

    n/a
    		 -86.25%

    50-Day Moving Average

    n/a
    		 1.27

    200-Day Moving Average

    n/a
    		 2.81

    Relative Strength Index (RSI)

    n/a
    		 27.33

    Average Volume (20 Days)

    n/a
    		 21,590

    Income Statement

    In the last 12 months, LakeShore Biopharma Ltd had revenue of 573.42M and earned -433.46M in profits. Earnings per share was -4.05.

    Revenue

    n/a
    		 573.42M

    Gross Profit

    n/a
    		 455.73M

    Operating Income

    n/a
    		 -445.83M

    Net Income

    n/a
    		 -433.46M

    EBITDA

    n/a
    		 -368.66M

    EBIT

    n/a
    		 -410.85M

    Earnings Per Share (EPS)

    n/a
    		 -4.05
    Full Income Statement

    Balance Sheet

    The company has 246.35M in cash and 424.46M in debt, giving a net cash position of -178.11M.

    Cash & Cash Equivalents

    n/a
    		 246.35M

    Total Debt

    n/a
    		 424.46M

    Net Cash

    n/a
    		 -178.11M

    Retained Earnings

    n/a
    		 -2.31B

    Total Assets

    n/a
    		 1.51B

    Working Capital

    n/a
    		 100.94M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -295.23M and capital expenditures -44.25M, giving a free cash flow of -339.48M.

    Operating Cash Flow

    n/a
    		 -295.23M

    Capital Expenditures

    n/a
    		 -44.25M

    Free Cash Flow

    n/a
    		 -339.48M

    FCF Per Share

    n/a
    		 -3.17
    Full Cash Flow Statement

    Margins

    Gross margin is 79.48%, with operating and profit margins of -77.75% and -75.59%.

    Gross Margin

    n/a
    		 79.48%

    Operating Margin

    n/a
    		 -77.75%

    Pretax Margin

    n/a
    		 -79.38%

    Profit Margin

    n/a
    		 -75.59%

    EBITDA Margin

    n/a
    		 -64.29%

    EBIT Margin

    n/a
    		 -77.75%

    FCF Margin

    n/a
    		 -59.2%

    Dividends & Yields

    LSB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for LSB.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Oct 4, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -2.43

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist